Author

Aleksandr Bykov

St. Anna Children's Cancer Research InstituteORCID 0000-0003-4532-9865Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1

Frequent Co-Authors

Florian HalbritteriD· 2 shared Alma DupanoviciD· 1 shared Anna R. PoetschiD· 1 shared Barbara Sax· 1 shared Boris KovačiciD· 1 shared Branka Radic-SarikasiD· 1 shared Dagmar GotthardtiD· 1 shared Dagmar SchinnerliD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Florian HalbritterORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyCell ReportsPeer-reviewedMar 1, 2025

YAP1 is a key regulator of EWS::FLI1-dependent malignant transformation upon IGF-1 mediated reprogramming of bone mesenchymal stem cells

Rahil Noorizadeh, Barbara Sax, Tahereh Javaheri…·Heinrich Kovar

The paper shows that IGF-1 reprograms bone mesenchymal stem cells in EWS::FLI1-mutant mice, leading to tumor formation, with Yap1 playing a central role, and suggests combined IGF-1R and YAP/TEAD inhibition as a potential treatment.

11 citations

mouseexperimental assay

𝕏 PostBluesky

Cancer BiologyCancer Immunology ResearchPeer-reviewedDec 6, 2024

Natural killer cell cytotoxicity shapes the clonal evolution of B cell leukaemia

Michelle C. Buri, Mohamed R. Shoeb, Aleksandr Bykov…·Eva Maria Putz

This study shows NK cells influence all phases of cancer immunoediting in B-ALL, promoting resistant clones through selective pressure and identifying LY6E as a marker of poor prognosis.

4 citations

mousehuman

𝕏 PostBluesky